Talazoparib + Enzalutamide seems to be the best combo: post hoc analysis
A statistical method, Matching-Adjusted Indirect Comparison (MAIC), has been used to evaluate the effectiveness of different PARP inhibitor combinations for treating metastatic castration-resistant prostate cancer (mCRPC).
The study, published on Nature, found that a combination of talazoparib and
A statistical method, Matching-Adjusted Indirect Comparison (MAIC), has been used to evaluate the effectiveness of different PARP inhibitor combinations for treating metastatic castration-resistant prostate cancer (mCRPC).
The study, published on Nature, found that a combination of talazoparib and